Seeking CCL3 inhibitors that effectively block the CCL3-CCR5/CCR1 axis in AD, preferably with evidence of crossing the BBB and modulating neuroinflammatory pathways (e.g., NF-κB/BACE1 suppression). Any insights on neutralizing antibodies vs. small-molecule approaches?
Hello, Chloe Sun
We have not found any selective small molecule inhibitors targeting CCL3.
You can refer to the S1P1 agonist IMMH00 (HY-147660, MCE) to see if it meets the experimental requirements. This compound can reduce the levels of chemokines and proinflammatory cytokines, including IL-1β, IL-5, IL-18, IP10, CCL3 and CCL5.
If you require small molecule compounds to have higher specificity for CCL3, you can consider building an siRNA interference model, such as the humanized CCL3 pre-designed siRNA set (HY-RS02099, MCE) sold by MCE, which has high specificity and transfection ability.
If you are interested in conducting siRNA experiments and would like to consult further experimental design, please continue to contact us.
The answer to this question comes from MedChemExpress (MCE) Technical Support.
- Badges
- Science topic
- Similar topics
- Biological Science
- Anatomy
- Tissue